Randomized phase 2 trial of CPX-351 vs. CLAG-M (cladribine, cytarabine, G-CSF, and mitoxantrone) for medically unfit adults with acute myeloid leukemia or other high-grade myeloid neoplasms
Anna B. Halpern(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Roland B. Walter(Rafael Advanced Defense Systems (Israel)), Jason P. Cooper(University of Washington), Erik L. Kimble(University of Washington), Megan Othus(Cancer Research And Biostatistics), Jacob Appelbaum(National Cancer Institute), Kathryn Russell(University of Washington), Bart L Scott(Fred Hutch Cancer Center), Joshua Veatch(University of Washington), Mary‐Elizabeth M. Percival(Fred Hutch Cancer Center), Raya Mawad(Fred Hutch Cancer Center), Sioḃán Keel(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa), Ryan D. Cassaday(University of Washington), Max Smith(Fred Hutch Cancer Center), Paul C. Hendrie(University of Washington), Cristina Ghiuzeli(University of Washington), Vivian G. Oehler(Cape Town HVTN Immunology Laboratory / Hutchinson Centre Research Institute of South Africa)
Cited by 0
Related Papers
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2021|714
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
|The Lancet Oncology|2014|703